Treatment of migraine with BMS180048: Response at 2 hours

Headache

Volumn 36, Issue 9, 1996, Pages 523-530

  Couch Jr , James R ^a   Saper, Joel ^b   Meloche, Jacques P ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Michigan Hd Pain Neurologic Inst   (United States)

^c Montreal Migraine Clinic   (Canada)

Author keywords

BMS180048; migraine

Indexed keywords

ANTIMIGRAINE AGENT; AVITRIPTAN; DIHYDROERGOTAMINE; PLACEBO; SEROTONIN 1 AGONIST; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

ADULT; ARTICLE; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECURRENCE; SEROTONIN AGONISTS; SULFONAMIDES; TIME FACTORS; TRYPTAMINES;

EID: 0029983953     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1996.3609523.x     Document Type: Article

References (28)

1. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992;13:307-311.
2. 1D agonist 311C90. Headache. 1994;34:299. Abstract.
3. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991;12:444-446.
4. Peroutka SJ. The pharmacology of current anti-migraine drugs. Headache. 1990;30(suppl 1):5-11.
5. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
6. Mathew NT, Dexter J, Couch J, et al on behalf of the US Sumatriptan Research Group. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. Arch Neurol. 1992;49:1271-1276.
7. The Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991;31:323-331.
8. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168-171.
9. Tfelt-Hansen P, Lipton RB. Dihydroergotamine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993.
10. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-321.
11. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
12. Dahlof C. Headache recurrence after subcutaneous sumatriptan and early treatment. Lancet. 1992;340:909.
13. Saadah HA. Abortive headache therapy with intramuscular dihydroergotamine. Headache. 1992;32:18-20.
14. Sheftell FD, Weeks RE, Rapoport AM, Siegel S, Baskin S, Arrowsmith F. Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with acute migraine in a tertiary care center. Headache. 1994;34:67-72.
15. Kelly KM. Cardiac arrest following use of sumatriptan. Neurology. 1995;45:1211-1213.
16. Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH. Postmarketing study of cardiovascular adverse reactions associated with sumatriptan. BMJ. 1993;307:1185.
17. Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ. 1992;304:1415.
18. Ottervanger JP, Paalman HJA, Boxma GL, Stricker BH. Transmural myocardial infarction with sumatriptan. Lancet. 1993;341:861-862.
19. Curtin T, Brooks AP, Roberts JA. Cardiorespiratory distress after sumatriptan given by injection. BMJ. 1992;305:713-714.
20. Sarbin N, Gylys J, Iben L, et al. The receptor binding and vascular in vitro pharmacological profile of BMS-180048, a novel antimigraine agent. FASEB J. 1995;9:A347. Abstract.
21. Yocca F, Gylys J, Buchanan J, et al. Effect of BMS-180048 on carotid arterial blood flow and arteriovenous blood oxygen content in the anesthetized dog. FASEB J. 1995;9:A23. Abstract.
22. Patten JP for the Oral Sumatriptan Dose-Defining Study Group. Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. J Neurol. 1991;238(suppl 1):S62-S65.
23. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol. 1991;31:314-322.
24. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31:306-313.
25. The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan - an oral dose-defining study. Eur Neurol. 1991;31:300-305.
26. Goadsby PG, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet. 1991;338:782-783.
27. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol. 1992;32:177-184.
28. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol. 1994;241:138-144.